India likely to approve AstraZeneca vaccine by next week: Sources



India is likely to approve Oxford/AstraZeneca’s for emergency use by next week after its local manufacturer submitted additional data sought by authorities, two sources with knowledge of the matter told Reuters on Tuesday.


This could be the first country to give the regulatory green light for the British drugmaker’s vaccine as the British medicine regulator continues to examine data from the trials.


India, the world’s biggest vaccine-making country, wants to start inoculating its citizens next month and is also considering emergency use authorisation applications for vaccines made by Pfizer Inc and local company Bharat Biotech.




Getting vaccines to the world’s second-most populous country with one of the highest infection rates will also be a big step in the battle against the pandemic.


The AstraZeneca-Oxford shot is considered vital for lower-income countries and those in hot climates because it is cheaper, easier to transport and can be stored for long periods at normal fridge temperatures.


India’s Central Drugs Standard Control Organization (CDSCO) first reviewed the three applications on Dec. 9 here and sought more information from all the companies, including from (SII), which is making the shots.


ALSO READ: ‘It’s nightmarish’: Uphill task as Bharat Biotech gears for vaccine rollout


SII, the world’s biggest vaccine manufacturer, has now provided all the data, the two sources said. The authorities were still waiting for more details from Pfizer, a government health adviser told here a news briefing on Tuesday, while one of the sources said additional information was expected from Bharat Biotech.


Both sources said Indian health officials were in direct contact with their British counterparts over the shot and that there were “strong indications” an approval would come by next week.


The expected approval comes after data from AstraZeneca’s late-stage trials in the UK and Brazil released earlier this month showed the vaccine had efficacy of 62% for trial participants given two full doses, but 90% for a smaller sub-group given a half, then a full dose.


ALSO READ: 2021 Outlook: Covid vaccine, economic recovery, earnings to drive markets


The Indian regulator is only considering the two full-dose regimen of the shot despite it showing a lower success rate, the sources said.


“Serum is ready,” said one of the sources. “Initially, we may get around 50 million to 60 million doses.”


The sources declined to be named as deliberations were ongoing and the timeline could change.


CDSCO chief V.G. Somani did not immediately respond to a request for comment. Bharat Biotech and Pfizer declined to comment, while SII did not immediately respond to an email seeking comment.


India has not yet signed a vaccine supply deal with any company, but SII has already stockpiled more than 50 million doses of the shot and plans to make a total of 400 million doses by July.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor





Source link

Leave a Comment

Your email address will not be published. Required fields are marked *